Severe Pulmonary Toxoplasmosis Mimicking Viral Pneumonitis after a Third Allogeneic Stem Cell Transplantation in a Man with Acute Lymphoblastic Leukemia

Masahiko Sumi¹, Satoru Hata², Keijiro Sato¹, Yuku Fujikawa¹, Ikuo Shimizu¹, Toshimitsu Ueki¹, Daigo Akahane¹, Mayumi Ueno¹, Naoaki Ichikawa¹ and Hikaru Kobayashi¹

Abstract

A 22-year-old man with acute lymphoblastic leukemia underwent allogeneic stem cell transplantation (allo-SCT) twice, then underwent allo-SCT a third time due to relapse. On day 27, he developed acute respiratory distress, and bilateral interstitial infiltrates were noted on CT images. Despite receiving intensive treatment, the patient died on day 32 from progressive respiratory failure. An autopsy revealed evidence of diffuse alveolar damage caused by the genus Toxoplasma. At present, toxoplasmosis is considered to be a rare infectious complication in Japan. However, the actual incidence of toxoplasmosis may be higher than currently believed due to a lack of suspicion of the diagnosis in patients, difficulty in making a diagnosis and low autopsy rates.

Key words: Toxoplasma gondii, pulmonary toxoplasmosis, stem cell transplantation, acute lymphoblastic leukemia

(Intern Med 51: 2943-2947, 2012)  
(DOI: 10.2169/internalmedicine.51.7837)

Introduction

Toxoplasma gondii (T. gondii) is a ubiquitous intracellular protozoan. In immunocompetent individuals, T. gondii causes asymptomatic infection or fever and lymphadenopathy. However, in immunocompromised patients, T. gondii may cause fulminant disseminated infection (1). Toxoplasmosis occurring after hematopoietic stem cell transplantation (HSCT) is a rare but often fatal complication (2-8). In HSCT recipients, toxoplasmosis infection is usually the result of reactivation of a latent infection rather than the development of a primary infection. The incidence of toxoplasmosis in HSCT recipients shows marked geographical variation depending on local pet-keeping habits, especially the presence of cats, and food contamination with cysts (1). In countries with high endemicity, such as France, specific antibodies can be detected in 50-80% of the general adult population (1, 2, 9). In Japan, specific antibodies can be detected in only 10% of the population (4, 9). Although the incidence of toxoplasmosis after HSCT in Japan is not well established, in the United States (US) and France, the incidence is reported to be 0.3% and 5%, respectively (5, 9). The most frequently involved organs are the central nervous system (CNS), lungs and heart, and making a diagnosis is very difficult, especially in patients with lung toxoplasmosis, because the clinical and radiological manifestations are non-specific (2, 10-12). We herein report a case of fatal pulmonary toxoplasmosis mimicking viral pneumonitis in an HSCT recipient that was diagnosed postmortem.

Case Report

A 22-year-old man was admitted to our hospital in De-
A diagnosis of precursor B lymphoblastic leukemia was made. The patient had a history of keeping a dog as a pet until one year before admission. He had occasionally eaten raw horsemeat (horsemeat sashimi) prior to admission. Although the patient had achieved hematological complete remission (CR) following the administration of induction chemotherapy, his leukemia relapsed in December 2007. He achieved a second CR following the administration of reinduction chemotherapy, and a first allogeneic stem cell transplantation (allo-SCT) using bone marrow from a human leukocyte antigen (HLA)-matched unrelated donor was performed in May 2008. The conditioning regimen for the first allo-SCT consisted of 60 mg/kg of cyclophosphamide for two days and six fractionated total body irradiation (TBI) treatments (total: 12 Gy). Tacrolimus and short-term methotrexate were used for prophylaxis against graft-versus-host disease (GVHD). The patient’s pre-first transplantation serological test was positive for Toxoplasma gondii. The patient developed grade 2 acute skin GVHD and limited-type chronic skin GVHD. However, the leukemia relapsed in January 2009 and a second allo-SCT from HLA 2 antigen-mismatched cord blood was performed in a non-remission state in February 2009. The conditioning regimen for the second allo-SCT consisted of 25 mg/m² of fludarabine for five days, 40 mg/m² of melphalan for two days and two fractionated TBI treatments (total: 4 Gy). Tacrolimus was used for GVHD prophylaxis. The patient achieved a third CR and developed grade 2 acute skin GVHD and limited-type chronic skin GVHD. However, another relapse with 36.0% marrow infiltration by leukemic blasts. Antimicrobial therapy and supportive therapy, including corticosteroids (prednisolone: 1.4 mg/kg), parenteral nutrition, diuretics, low-dose dopamine and albumin recruitment were initiated, resulting in the gradual resolution of VOD; however, the marked fever remained. On day 22, neutrophil engraftment was achieved. However, on day 27, the patient developed acute respiratory distress, hypoxemia and bilateral interstitial infiltrates on chest X-ray (Fig. 1A). The chest CT images showed ground glass attenuation with coarse nodular opacities. On day 29, the patient died as a result of respiratory failure. At autopsy, the lungs were found to be congested, and co-
The real incidence of toxoplasmosis is unknown because making an accurate diagnosis is often difficult. In the present case, if an autopsy had not been performed, the cause of death would have been considered viral pneumonia. In countries with a high incidence of toxoplasmosis infection, much progress has been made in the early detection of toxoplasmosis after allo-SCT with serial screening of peripheral blood for T. gondii DNA using polymerase chain reaction (PCR). Martino et al. reported the results of a prospective study of the incidence of reactivation of toxoplasmosis in five European transplantation centers. Toxoplasmosis infection was evaluated using PCR for T. gondii DNA in peripheral blood in 106 seropositive adult recipients of HSCT (3). In that report, 16 patients (16%) had PCR results of peripheral blood specimens that were positive for T. gondii. Although all 16 patients with positive PCR results received anti-Toxoplasma therapy after the positive results were revealed, six patients developed Toxoplasma disease, four developed localized encephalitis, one developed pulmonary disease with rapid dissemination and one developed acute disseminated disease. The latter two patients died. In a retrospective study in Japan, it was reported that the incidence of toxoplasmosis among seropositive recipients of allo-SCT is 2.1% (4), which is lower than that reported in the prospective study by Martino et al. This discrepancy highlights the difficulties of accurately diagnosing toxoplasmosis. The real incidence of toxoplasmosis in Japan may be higher, as lack of suspicion of the disease, difficulty in making a diagnosis and low autopsy rates all contribute to lowering the reported incidence. In Japan, multicenter prospective studies are needed to investigate the real incidence of toxoplasmosis after HSCT.

Mele et al. reported the results of a systematic review of the literature involving 110 cases of toxoplasmosis following allo-SCT (5). Among the patients with disseminated toxoplasmosis, 80% died with a median survival time of 10 days postdiagnosis and 62.5 days post-allo-SCT. In the study, it was recommended that a diagnosis of disseminated toxoplasmosis should be considered if pulmonary signs and symptoms and/or fever occur in recipients with a risk of reactivation between 30 and 100 days post-allo-SCT (5). However, in cases of disseminated disease, including those with lung or heart involvement, it is very difficult to make an accurate diagnosis and administer appropriate therapy because of the drastic clinical course. In the present case, there

Figure 2. The pathological findings in the lungs at autopsy. Many alveoli contained cells packed with tachyzoites of T. gondii (arrows) associated with the development of fibrinous or fibrinopurulent exudates. A: Hematoxylin and Eosin staining (original magnification, ×400). B: Immunohistochemical staining of T. gondii (original magnification, ×400).
were only six days between the onset of symptoms and death. Performing PCR for \textit{T. gondii} in peripheral blood, cerebrospinal fluid and bronchoalveolar lavage fluid is a useful diagnostic tool for detecting toxoplasmosis (3, 7, 12, 14, 15). However, PCR for \textit{T. gondii} is a time-consuming method because it is not performed routinely in Japan. Laibe et al. reported a case of disseminated toxoplasmosis diagnosed using a Diff-Quick-stained sputum smear analysis (16). Sputum is readily obtainable, even from severely ill patients, and its analysis can be performed immediately. Therefore, careful sputum analysis may allow for accurate diagnosis of pulmonary toxoplasmosis.

Administering prophylaxis or preemptive therapy is a reasonable choice for preventing fatal toxoplasmosis. Two drug combinations have been proven to be efficient in preventing toxoplasmosis in allo-SCT recipients: T/S and pyrimethamine-sulfadoxine (9). In the present case, T/S was administered and toxoplasmosis did not develop after the second allo-SCT. Derouin et al. proposed that prophylaxis for toxoplasmosis should be initiated after 30 days post-allo-SCT, as 90% of cases of toxoplasmosis occur during this time (9). Moreover, they proposed that, if delayed prophylaxis is preferred, weekly follow-up of the recipient using PCR of peripheral blood is recommended for high-risk patients during the entire period without prophylaxis. A study reported by Martino et al. suggested that PCR-based preemptive therapy may prevent death due to toxoplasmosis infection in approximately 80% of patients who develop \textit{Toxoplasma} reactivation. In that study, higher PCR density, non-early disease status, second HSCT, cord blood transplantation and a lack of prophylaxis with T/S were each found to be associated with an increased incidence of infection according to a univariate analysis (3). Aoun et al. reported the highest risk to be in patients with a haploidentical donor type in their single-center retrospective study (17). The present patient might have had an extremely high risk of reactivation because he was treated three times with allo-SCT, received corticosteroid therapy for hemophagocytosis and could not receive prophylaxis with T/S due to liver dysfunction following VOD. In a case like this, preemptive therapy may be a more promising strategy (3, 14).

At present, toxoplasmosis is considered to be a rare infectious complication in Japan. However, the incidence of toxoplasmosis may increase because the frequency of performing allo-SCT causing a highly immunosuppressive state (e.g. cord blood or haploidentical stem cell transplantation) is increasing gradually in Japan (18, 19). Therefore, physicians should be aware that fatal toxoplasmosis can occur in HSCT patients, and further studies involving a larger number of cases are required to develop strategies to overcome this severe infectious complication. We propose testing all allo-SCT candidates for \textit{Toxoplasma} IgG positivity to determine who is at risk for reactivation. Seropositive recipients with a high risk of reactivation should receive prophylactic therapy for \textit{Pneumocystis jirovecii} with T/S instead of pentamidine whenever possible. However, several reports have described toxoplasmosis occurring in spite of prophylaxis with T/S. Therefore, routine PCR testing of peripheral blood specimens may be necessary in order to make early diagnoses to avoid fatal toxoplasmosis.

The authors state that they have no Conflict of Interest (COI).

References
16. Laibe S, Ranque S, Curtilliet C, Faraut F, Dumon H, Franck J. Timely diagnosis of disseminated toxoplasmosis by sputum exami-